Literature DB >> 32148339

Positive feedback through inflammation creates bistable behavior in HIV tissue sanctuaries.

Aditya Jagarapu1, Rajveer Mann2, Michael J Piovoso3, Ryan Zurakowski1.   

Abstract

Combination Antiretroviral Therapy (cART) consists of a cocktail of drugs administered to HIV-infected patients that can suppress the amount of HIV in the patient's blood plasma to an undetectable level. Our previous work has suggested that some HIV-infected patients, despite being placed on cART, can still have ongoing viral replication occurring in self-sustaining inflamed lymph node follicle sanctuary sites. Spatial models of the putative sites show that inflammation is a necessary condition for ongoing HIV replication. In this study, we model the hypothesis that ongoing HIV replication may provide a sufficiently strong pro-inflammatory signal to maintain inflammation levels consistent with continued HIV replication. A system of ordinary differential equations integrated with a reactive-diffusion system is used to model the HIV dynamics and the diameter of a lymph node follicle as a function of time and external influence. The estimates of the parameters in our model come from prior data when available. The results of our study show that these dynamics have two stable steady-state solutions, one with low inflammation and no ongoing HIV replication in the site, and one with high inflammation and high levels of ongoing HIV replication in the site. We furthermore show that the system can transition between the two outcomes in response to a transient exogenous addition of pro-inflammatory signaling, consistent with the antigenic stimulus of a secondary infection. The spatial isolation of the sites results in a low viral load in the blood plasma for both conditions.

Entities:  

Year:  2019        PMID: 32148339      PMCID: PMC7060373          DOI: 10.23919/acc.2019.8815245

Source DB:  PubMed          Journal:  Proc Am Control Conf        ISSN: 0743-1619


  24 in total

1.  Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.

Authors:  T W Chun; R T Davey; M Ostrowski; J Shawn Justement; D Engel; J I Mullins; A S Fauci
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

2.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.

Authors:  Courtney V Fletcher; Kathryn Staskus; Stephen W Wietgrefe; Meghan Rothenberger; Cavan Reilly; Jeffrey G Chipman; Greg J Beilman; Alexander Khoruts; Ann Thorkelson; Thomas E Schmidt; Jodi Anderson; Katherine Perkey; Mario Stevenson; Alan S Perelson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

3.  HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.

Authors:  L Ruiz; G Carcelain; J Martínez-Picado; S Frost; S Marfil; R Paredes; J Romeu; E Ferrer; K Morales-Lopetegi; B Autran; B Clotet
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

4.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

5.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

6.  Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Authors:  Melanie A Thompson; Judith A Aberg; Jennifer F Hoy; Amalio Telenti; Constance Benson; Pedro Cahn; Joseph J Eron; Huldrych F Günthard; Scott M Hammer; Peter Reiss; Douglas D Richman; Giuliano Rizzardini; David L Thomas; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2012-07-25       Impact factor: 56.272

7.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

8.  Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection.

Authors:  Simon D W Frost; Javier Martinez-Picado; Lidia Ruiz; Bonaventura Clotet; Andrew J Leigh Brown
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

9.  Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.

Authors:  E Fabian Cardozo; Rutao Luo; Michael J Piovoso; Ryan Zurakowski
Journal:  J Theor Biol       Date:  2013-12-28       Impact factor: 2.691

10.  Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial.

Authors:  Alain Lafeuillade; Assi Assi; Cécile Poggi; Caroline Bresson-Cuquemelle; Eric Jullian; Catherine Tamalet
Journal:  AIDS Res Ther       Date:  2014-10-07       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.